Cargando…

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

Darunavir/ritonavir monotherapy maintains HIV suppression in most patients who have achieved an undetectable viral load on combination antiretroviral treatment, and is increasingly used in the clinic. However, concerns have been raised about the effectiveness of ritonavir-boosted protease inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gisslén, Magnus, Fuchs, Dietmar, Hagberg, Lars, Svennerholm, Bo, Zetterberg, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2012
Materias:	Case-Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507278/ https://www.ncbi.nlm.nih.gov/pubmed/22776013 http://dx.doi.org/10.3109/00365548.2012.690526

Ejemplares similares

Cerebrospinal Fluid Viral Load and Intrathecal Immune Activation in Individuals Infected with Different HIV-1 Genetic Subtypes
por: Abdulle, Sahra, et al.
Publicado: (2008)

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
por: Ferretti, Francesca, et al.
Publicado: (2016)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection
por: Peterson, Julia, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia – case report
por: Andersson, Lars-Magnus, et al.
Publicado: (2006)

Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients
por: Lopez-Ruz, Miguel A., et al.
Publicado: (2016)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection
por: Price, Richard W., et al.
Publicado: (2013)

Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study
por: Jespersen, Sofie, et al.
Publicado: (2016)

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy
por: Yilmaz, Aylin, et al.
Publicado: (2013)

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
por: Mäkitalo, Signar, et al.
Publicado: (2015)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression
por: Gisslen, Magnus, et al.
Publicado: (2021)

Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance
por: Hagberg, Lars, et al.
Publicado: (2020)

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection
por: Hagberg, Lars, et al.
Publicado: (2010)

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study
por: Yilmaz, Aylin, et al.
Publicado: (2006)

Cohort profile: a longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid – the Gothenburg HIV CSF Study Cohort
por: Hagberg, Lars, et al.
Publicado: (2023)

Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection
por: Ahlgren, Erika, et al.
Publicado: (2016)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms
por: Edén, Arvid, et al.
Publicado: (2022)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection
por: Gisslén, Magnus, et al.
Publicado: (2005)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study
por: Mandelbrot, Laurent, et al.
Publicado: (2023)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy
por: BenMarzouk-Hidalgo, Omar J., et al.
Publicado: (2015)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation
por: Cheng, Da, et al.
Publicado: (2022)

Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients
por: Jessen Krut, Jan, et al.
Publicado: (2014)

CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection
por: Gisslén, Magnus, et al.
Publicado: (2018)

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
por: Colbers, Angela, et al.
Publicado: (2015)

Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study
por: Santos, José R., et al.
Publicado: (2013)

Blood–brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV
por: Anesten, Birgitta, et al.
Publicado: (2016)

Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
por: Bremell, Daniel, et al.
Publicado: (2013)

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fqkgvcs2p5asdhmoncp66i3q9m